Speaker Profile
M.D., Ph.D., CMO, Kyverna Tx
Biography
James Chung, MD, PhD, is Chief Medical Officer at Kyverna Therapeutics. Dr. Chung brings extensive commitment to the autoimmune field within the biopharmaceutical industry working across the entire drug development process. Prior to Kyverna, Dr. Chung began in Early Development and served as the Inflammation Therapeutic Area Head. He also worked in latestage development as the Global Development Leader for Enbrel and as the Inflammation head for the US and Global Medical Organizations. Dr. Chung obtained his MD and PhD in immunology at the University of Pennsylvania where he also completed his residency in Internal Medicine and fellowship in Rheumatology.
Talk
Transformative Outcomes With CART Cell Therapy for Autoimmune Diseases
Kyverna Therapeutics is working to transform outcomes for patients with autoimmune diseases with KYV101, a fully human antiCD19 CAR Tcell therapy with structural features that confer a safety profile well suited for use in autoimmune diseases. Kyverna has treated patients with multiple autoimmune diseases in sites around the world.
Session Abstract – PMWC 2024 Silicon Valley
Track Co-Chairs:
Yael Weiss, Mahzi Tx
Peter Marks, FDA
- PMWC 2024 Award Ceremony
Pioneer Honoree: Katherine A. High, AskBio
Pioneer Honoree: Timothy Yu, Boston Children's Hospital
- Piloting Interventional Genomics for Orphan Diseases
Keynote: Timothy Yu, Boston Children's Hospital
- Accelerated Approval for Small Populations: Biomarkers & Endpoints (PANEL)
Chair: Peter Marks, FDA
- Jennifer Puck, UCSF
- Katherine A. High, Rockefeller University
- Jennifer Panagoulias, FAST (Angelman Syndrome Foundation)
- Timothy Yu, Boston Children's Hospital - Novel Clinical Design Approaches in Rare Diseases (PANEL)
Chair: Adam Shaywitz, Bridge Bio
- Salvador Rico, Encoded Therapeutics
- Eric Crombez, Ultragenyx
- Elizabeth Berri Kravis, Rush University
- Empowering Patient Advocacy in Rare Disease Therapies (PANEL)
Chair: Yael Weiss, Mahzi Tx
- Charlene Son Rigby, STXBP1 Foundation
- Michael Graglia, Syngap Research Fund
- Wendy Erler, Alexion Pharmaceuticals - Advancing the Frontier: Gene Editing for Rare Diseases (PANEL)
Chair: Matthew Porteus, Stanford
- David Lebwohl, Intellia Therapeutics
- Pooja Agarwal, BioMarin Pharmaceutical
- James Chung, Kyverna Therapeutics
- Lucas Harrington, Mammoth Biosciences - Advancing the Frontier: Gene and Cell Therapies for Rare Diseases (PANEL)
Chair: Morten Sogaard, Astellas Gene Therapies
- Swati Tole, Capsida Biotherapeutics
- David Kirn, 4dmt
- Adrian Veres, Dyno Therapeutics
- Thomas Wechsler, J&J
- PMWC Showcase
- Dominic Borie, Kyverna Therapeutics
